B
Bull
Bull · 25%IKNA
$1.63
Scenario price
$17.160
+0.752 (+4.38%)At close
Loading chart…
- High
- 17.755
- Open
- 16.560
- VWAP
- 17.08
- Vol
- 38.10K
- Mkt Cap
- 84.45M
- Low
- 16.320
- Amount
- 650.77K
- EV/EBITDA, TTM
- 0.70
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Valuation Metrics
The current forward P/E ratio for ImageneBio Inc (IKNA) is -1.74, compared to its 5-year average forward P/E of -2.79.
Alphio AI Price Scenarios for IKNA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
2.007-27TipRanksUpcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
8.507-25NewsfilterInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
8.507-15NewsfilterIkena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
- 8.507-11NASDAQ.COM
ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger
5.003-28NewsfilterTraws Pharma Announces Management Updates
IKNA FAQ — answered by Alphio AI
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.